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INTRODUCTION
Several desensitization protocols have been developed to pre-
vent antibody-mediated acute rejection (AMR) of kidney allo-
grafts, and this has increased the success rate of transplanta-
tion in sensitized recipients. However, protocols differ between
centers and have different clinical outcomes, and comparisons
have been difficult because of differences in patient character-
istics, the assays used to define the presence and level of donor-
specific antibody (DSA), and the assessment of outcomes (1).
Intravenous immunoglobulin (IVIG) and/or plasmapheresis
(PP) are basic desensitization strategies (1-8), and anti-CD20
antibody is also included in some centers (2, 9-13). This study
reports our experience of living donor renal transplantation
in highly sensitized patients. The basic desensitization pro-
tocol included pretransplant PP and low dose IVIG, with the
recent addition of anti-CD20 antibody to the basic protocol.
Here we discuss the rationale of using PP and low dose IVIG
and the clinical significance of anti-CD20 antibody in desen-
sitization.
MATERIALS AND METHODS
Patients
A retrospective review was performed of 10 highly sensi-
tized patients treated with PP/IVIG or PP/IVIG/rituximab
prior to living donor renal transplantation between January
2003 and May 2007. Highly sensitized patients were defined
as those who had previous or current positive crossmatch tests
either by antihuman globulin-enhanced, complement-depen-
dent cytotoxicity (AHG-CDC) or by flow cytometry (FCM),
or patients who were retransplants and had PRA levels ≥50%.
Desensitization protocol
All 10 recipients underwent PP on transplant days -14, -
12, -10, -7, -5, and -3. Following each PP, patients received
200 mg/kg per body weight IVIG (Table 1). Two recipients
additionally received intravenous rituximab, an anti-CD20
antibody, at 375 mg/m2 body surface area on transplant days
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Successful Renal Transplantation with Desensitization in Highly
Sensitized Patients: A Single Center Experience
Intravenous immunoglobulin (IVIG) and/or plasmapheresis (PP) are effective in pre-
venting antibody-mediated rejection (AMR) of kidney allografts, but AMR is still a
problem. This study reports our experience in living donor renal transplantation in
highly sensitized patients. Ten patients with positive crossmatch tests or high levels
of panel-reactive antibody (PRA) were included. Eight patients were desensitized
with pretransplant PP and low dose IVIG, and two were additionally treated with rit-
uximab. Allograft function, number of acute rejection (AR) episodes, protocol biop-
sy findings, and the presence of donor-specific antibody (DSA) were evaluated. With
PP/IVIG, six out of eight patients showed good graft function without AR episodes.
Protocol biopsies revealed no evidence of tissue injury or C4d deposits. Of two patients
with AR, one was successfully treated with PP/IVIG, but the other lost graft function
due to de novo production of DSA. Thereafter, rituximab was added to PP/IVIG in
two cases. Rituximab gradually decreased PRA levels and the percentage of periph-
eral CD20+ cells. DSA was undetectable and protocol biopsy showed no C4d de-
posits. The graft function was stable and there were no AR episodes. Conclusive-
ly, desensitization using PP/IVIG with or without rituximab increases the likelihood
of successful living donor renal transplantation in sensitized recipients.
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-7 and -1. Crossmatch tests and PRA tests were performed on
transplant days -9 and -1. Follow-up PRA test was performed
3 days after transplantation. Additional tests were performed
if clinically indicated.
The goal of the desensitization protocol was to achieve a
negative crossmatch test (cases 1-8) or a PRA level of <20%
and no DSA (cases 9 and 10).
Characterization of alloantibody status and 
immunophenotyping of lymphocytes
Crossmatch tests were performed using the AHG-CDC
assay and FCM. A positive crossmatch by FCM was defined
as a displacement of the mean channel fluorescence (MCF)
by more than 10 channels relative to a negative control and
donor autologous control. Although we did not check medi-
an channel shift, we confirmed positive cases by relative medi-
an fluorescence (test MCF [recipient autologous MCF+donor
autologous MCF+healthy autologous MCF]/3) ≥1.5 and
test MCF greater than the negative MCF+3SD.
PRA levels were determined by enzyme-linked immunosor-
bent assays (ELISA) (LAT, One Lambda Inc., CA, U.S.A.). In
PRA-positive cases, LAT1240 (LAT Class I and II) was used
for the documentation of DSA. Subsequent crossmatch tests
and PRA tests were performed after the third and sixth PP/
IVIG in all patients (Table 1). In two patients who received
rituximab, an antibody monitoring system (AMS, GTI Inc.,
WI, U.S.A.) was also used before and after desensitization.
AMS is a solid-phase ELISA crossmatch test for detecting IgG
antibody to the donor-specific solubilized HLA class I and
class II antigens. We previously reported that AMS is useful
as a supportive crossmatch test or as a monitoring test for
detecting class I or II DSA (14). Eight recipients underwent
transplantation after achieving a negative crossmatch by both
AHG-CDC and FCM and no DSA. Two patients who received
rituximab underwent transplantation after achieving PRA
levels <20% and no DSA confirmed by PRA and AMS.
In patients who received rituximab, venous blood samples
for lymphocyte immunophenotyping were collected in EDTA
tubes. The percentages of CD4
+, CD8
+, and CD19
+ lympho-
cytes were assessed by FCM before and after infusion of rit-
uximab.
Immunosuppression
Maintenance immunosuppression consisting of tacrolimus
(FK506), mycophenolate mofetil (MMF) and prednisone was
started seven days prior to transplantation (Table 1). The ini-
tial dose of FK506 was 0.1 mg/kg per day by the oral route,
which was increased to 0.16 mg/kg per day after transplan-
tation. The target trough levels were 10-15 ng/mL in the first
three months and 5-10 ng/mL thereafter. The initial dose of
MMF was 1.5 g/day, and the dose was reduced in response to
adverse effects such as diarrhea or leucopenia. Methylpred-
nisolone was administered by intravenous infusion (125 mg/
day) for seven days prior to transplant, increased to 1 g/day
on transplant day 0 then tapered to an oral dose of 30 mg/
day prednisone on posttransplant day 4. For induction ther-
apy, basiliximab was administered intravenously (20 mg) on
transplant days 0 and +4.
Renal allograft biopsies
A surveillance (protocol) biopsy was routinely performed
on stable allografts on day 14 after transplantation. Stable
graft function was defined as less than 20% increase in serum
creatinine concentration in the three days before biopsy and
no increase in the dose of immunosuppressive drugs. An indi-
cation biopsy was performed in cases of allografts that showed
greater than 20% increase in serum creatinine concentration.
An 18-gauge biopsy gun was used after ultrasonic localization
of the allograft. The minimum criteria for tissue adequacy
were six or more glomeruli and at least one arterial cross-sec-
tion. Indirect immunofluorescence (IF) staining was performed
using monoclonal antibodies against complement protein C4d
(Biogenesis, Poole, U.K.; dilution 1:50) for detecting C4d depo-
sition. C4d positivity was defined as diffuse (>50%) and lin-
ear staining of peritubular capillaries (PTC). Histopatholog-
ical diagnosis was made according to the revised Banff 2001
criteria (15).
Day Procedure
-14 PP/IVIG
-12 PP/IVIG
-10 PP/IVIG
Run crossmatch tests and PRA
-7 Start FK506 (0.05 mg/kg, p.o. twice daily)
Start MMF (0.75 g, p.o. twice daily)
Start methylprednisolone (125 mg i.v. once daily)
PP/IVIG
Rituximab (375 mg/m
2 i.v.)
-5 PP/IVIG
-3 PP/IVIG
-1 Rituximab (375 mg/m
2 i.v.)
Run crossmatch tests and PRA
0 Transplantation
Basiliximab (20 mg i.v.)
Increase FK506 (0.08 mg/kg, p.o. twice daily)
Increase methylprednisolone (0.5 g, i.v. daily)
1, 2, 3 Taper methylprednisolone
Run PRA test on D3
4 Basiliximab (20 mg i.v.)
Change methylprednisolone to prednisone
(30 mg, p.o. once daily)
PP, plasmapheresis; IVIG, intravenous immunoglobulin; MMF, mycophe-
nolate mofetil; PRA, panel-reactive antibody.
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Clinical data and statistics
The following data were analyzed: 1) demographic and im-
munologic characteristics of patients, 2) effect of desensitiza-
tion, 3) posttransplant allograft function and DSA, 4) histo-
logical findings of allograft biopsies, 5) rate of acute rejec-
tion (AR) and allograft loss, and 6) complications related to
transplantation. Descriptive values were presented as mean
±SD or median and range.
RESULTS
Patient demographics and immunologic status
Table 2 shows the demographic characteristics of 10 high-
ly sensitized patients who underwent desensitization during
the study period. All patients were ABO-compatible. Three
patients were retransplants, nine had previous transfusions,
and five had more than three HLA mismatches. Four female
recipients had previous pregnancy history. 
The results of crossmatch tests and PRA levels just before
desensitization are listed in Table 3. Six patients were cross-
match-positive, and four patients were crossmatch-negative
but had high PRA levels (≥50%). Of the crossmatch-neg-
ative patients, three had previous or current DSA detected
by PRA and two were retransplants.
Effect of desensitization
All 10 patients completed the desensitization protocol and
were able to undergo transplantation. Of six patients who were
crossmatch-positive, four patients became crossmatch-nega-
tive by both AHG-CDC and FCM after six PP/IVIG treat-
ments. In three patients with negative crossmatch tests, pre-
vious or current DSA detected by PRA became undetectable
after desensitization. In one patient, PRA levels increased after
PP/IVIG, but the crossmatch test was negative and DSA was
consistently undetectable by PRA. Of the eight patients who
had pretransplant PRA levels ≥20%, seven showed a decrease
in PRA levels. The mean decreases in class I and class II PRA
levels were 61.5% and 100%, respectively (Fig. 1).
Two patients did not achieve negative crossmatch tests
because they were treated with rituximab, which can inter-
fere with standard crossmatch tests (16). Instead, their alloan-
tibody status was monitored with PRA and AMS. In case 9,
class I PRA level decreased by 64.2%, class II PRA level de-
creased by 100%, and DSA (anti-A1) became undetectable.
In case 10, both class I and class II PRA levels decreased by
100%, and DSA (anti-A11 and anti-A33) became undetectable
(Fig. 1, 2). In both patients, crossmatch by AMS was posi-
tive in T cells before desensitization, and became negative
after desensitization. As shown in figure 3, peripheral CD19
+
Age (mean±SD, range) 47.5±8.4 (36-59)
Sex (M:F) 3:7
Etiology of renal failure Chronic GN 7
PCKD 1
Hypertension 1
Diabetes 1
Donor relation (RD:NRD) 6:4
No. of TX (1st:2nd:3rd) 7:2:1
HLA MM No. (mean±SD, range) 3.3±1.6 (0-5)
Previous transfusion units (mean±SD, range) 17.1±37.0 (0-120)
Dialysis method (HD:PD) 8:2
Mo. on dialysis (median, range) 16.0 (2.0-226.0)
M, male; F, female; Chronic GN, chronic glomerulonephritis; PCKD, poly-
cystic kidney disease; RD, related donor; NRD, nonrelated donor, TX,
renal transplantation; HLA MM No., number of HLA mismatches; HD,
hemodialysis; PD, peritoneal dialysis; Mo., months
Table 2. Demographics
*Patients 5 and 8 were previously crossmatch-positive by FCM for both T cells and B cells; 
� Previous DSA detected by PRA.
M, male; F, female; Prev TX, previous transplantation; Prev TF, previous transfusion; AHG-CDC, antihuman globulin-enhanced complement-dependent
cytotoxicity; FCM, flow-cytometry; PRA, panel-reactive antibody; DSA, donor-specific antibody.
Crossmatch test PRA (%)
DSA Patient Sex
No. of  No. of  No. of
prev TX prev TF pregn-ancy
AHG-CDC FCM
Class I Class II
TB T B
1F0 23--+ + 82.1 0 anti-A24, anti-A26
2F0 25--+ - 0 0 anti-A11
�
3F0 00--- - 71.4 0 anti-A24, anti-A30
4M0 2 0 --- + 0 0 undetected
5* F 0 2 0 --- - 57.1 25 anti-DR7
�
6 M 0 120 0 --- + 82.1 16.7 anti-A33, anti-B51
7F12 00--- - 35.7 50.0 undetected
8* F 1 20 5 --- - 90.0 0 anti-B54, anti-B70
9M2 2 0 --- + 50.0 25.0 anti-A1
10 F 0 1 3 1:2 1:2 + + 39.3 33.3 anti-A11
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cells, which represent the pool of B cells, were selectively deplet-
ed after infusion of rituximab. In contrast, CD4
+ or CD8
+ cells
were not affected.
Posttransplant allograft function, DSA, and subsequent
treatments
Seven patients showed immediate recovery of graft func-
tion (IGF), demonstrating active diuresis and rapid falls in
serum creatinine concentration. Two patients showed slow
recovery of graft function (SGF) without the need for dialy-
sis, but did not reach normal serum creatinine concentration
(1.2 mg/dL). One patient (case 8) showed IGF up to post-
transplant day 6, when abrupt oliguria developed. Subsequent
PP/IVIG and methylprednisolone therapy was needed in two
patients: patient 5 was treated for seven days postoperative-
ly, and patient 8 was treated for one day but lost graft func-
tion on posttransplant day 7. Posttransplant DSA monitor-
ing revealed no reemergence of DSA except in one patient
(case 8).
Histological findings of allograft biopsies
Of seven patients showing IGF, four underwent protocol
biopsies on posttransplant day 14. The histological findings
were nonspecific (Table 4), and no diffuse deposition of C4d
was found along the PTC. An indication biopsy was performed
in one patient (case 10) showing SGF on posttransplant day
10; however, the tissue specimen was inadequate for diagno-
sis. For the patient who underwent graft nephrectomy (case
Fig. 2. Change in PRA and DSA in patients who received rituximab. In patient 9, the level of class I PRA decreased by 64.2%, the level of
class II PRA decreased by 100%, and DSA (anti-A1) became undetectable. In patient 10, both class I and class II PRA levels decreased
by 100%, and DSA (anti-A11, anti-A33) became undetectable. The reduction in PRA levels lasted for 2-4 months in both patients.
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Fig. 1. Change in PRA before and after PP/IVIG treatment. Of eight patients who had pretransplant PRA levels ≥20%, seven showed a decrease
in PRA levels. The mean decreases in class I and class II PRA levels were 61.5% and 100%, respectively.
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8), histological analysis of the allograft showed acute cellu-
lar rejection grade IIB and thrombotic microangiopathy with
no C4d deposits. In the other four patients, biopsies were not
performed because of thrombocytopenia (n=2) or hematoma
around the allograft (n=2). 
Acute rejection and graft survival
There were two AR episodes in the early posttransplanta-
tion period. One (patient 5) presented as a slow decline in urine
output on posttransplant day 4 with no circulating DSA, and
was crossmatch-negative either by AHG-CDC or FCM. The
graft function improved with subsequent PP/IVIG and methyl-
prednisolone therapy. An indication biopsy was not performed
because of thrombocytopenia. The other (patient 8) present-
ed as accelerated acute rejection on posttransplant day 6 with
circulating DSA (anti-A2 and anti-B45). It resulted in graft
failure despite subsequent PP/IVIG and methylprednisolone
treatment. Graft nephrectomy was performed as signs of dis-
seminated intravascular coagulation occurred before trial of
Histological findings
Patient  Tubulitis/
Intimal arteritis/
Interstitial
tubular
Glomerulitis/ transmural arteritis/
inflammation
necrosis
capillaritis arterial fibrinoid
necrosis
1N D
2N D
3 -- - - - - - -
4 -- - - - - - -
5N D
6N D
7 -- - - - - - -
8+ + -- - + --
9 -- +(f) -- ---
10 ID
ND, biopsy not done; f, focal; ID, inadequate for diagnosis.
Table 4. Histological findings in allografts
Type Complication N Comment
Surgical Hematoma 2 1; Spontaneous resorption
complication 1; Surgical removal
Renal artery 1 Controlled with balloon
stenosis dilatation
Metabolic Diabetes 2 1; Controlled with oral agent
complication 1; Controlled with subcutaneous
insulin injection
Dyslipidemia 2
Osteoporosis 2
Infection Urinary tract 1 Excellent recovery
infection
Herpes zoster 1 Excellent recovery
BK-viremia 1 Excellent  recovery 
Table 5. Non-rejection complications directly related to trans-
plantation and immunosuppression
Fig. 3. Change in peripheral blood CD19 cells in patients who received rituximab. After infusion of rituximab (RTX), CD19
+ cells in the periph-
eral blood were selectively depleted, while CD4
+ or CD8
+ cells were not affected.
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Fig. 4. Change in mean serum creatinine concentration in function-
ing allografts. Nine patients are currently dialysis free after a medi-
an follow-up of 22.6 months (range: 6.9-52.0), and there have been
no more AR episodes. The latest serum creatinine concentration
is 1.0±0.2 mg/dL (range: 0.7-1.4).
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anti-thymoglobulin or OKT3. Nine patients are currently
dialysis-free after a median follow-up of 22.6 months (range:
6.9-52.0), and there have been no more AR episodes. The
most recent serum creatinine concentration is 1.0±0.2 mg/
dL (range: 0.7-1.4, Fig. 4). The patient survival rate is 100%.
Non-rejection complications
There was no procedure-related side effect of PP or infusion-
related side effect of rituximab. The non-rejection complica-
tions associated with transplantation or immunosuppression
are listed in Table 5. One patient developed BK-viremia and
BK-viruria 6 months after transplantation. There was no graft
dysfunction, and viremia was controlled after reducing the
dose of FK506. No patient developed CMV infection. 
DISCUSSION
The desensitization strategy at our center showed an excel-
lent clinical outcome compared to other reports (3, 4, 8). The
AR rate was 20% and graft loss rate was 10%. All function-
ing allografts have maintained stable graft function during
follow-up. This finding demonstrates that the desensitization
strategy is safe and effective in achieving successful transplan-
tation in sensitized patients.
There are several explanations for the excellent outcomes in
our center. First, we included patients with previously posi-
tive crossmatch tests or retransplants with PRA levels ≥50%,
as well as currently crossmatch-positive patients. Second, our
patients had low initial titers of DSA for T cells, and 30%
of patients were crossmatch-positive only for B cells. Third,
all patients were transplants from living donors, and 50%
were haploidentical for HLA. Fourth, protocol biopsies and
regular monitoring of PRA and DSA with AMS provided
more precise information about the status of allografts. One
may argue that patients with previously positive crossmatch
tests (patients 5 and 8) and retransplants with PRA levels
≥50% (patient 7) may not need desensitization treatment
before transplantation. However, these patients often show
high alloreactivity after transplantation (17) and result in severe
AMR and graft loss (18). Therefore we performed desensiti-
zation treatment. With regard to two patients with only B
positive FCM crossmatch, we also performed desensitization
treatment considering high risk of rejection and graft loss
(19, 20).
There is no standardized protocol for desensitization strat-
egy, but basic principle is elimination of preformed DSA, inhi-
bition of production of de novo DSA and strong maintenance
immunosuppression considering interaction between T and
B cells. We used six treatments of PP based on previous reports
that a minimum of four to a maximum of six cycles of pre-
transplant PP were sufficient to remove preformed DSA (1,
2, 7, 12). With respect to IVIG, there has been no random-
ized controlled trial comparing high dose IVIG and PP/low
dose IVIG. Protocols using IVIG are usually divided into
two groups, high dose IVIG (3-7 doses of 2 g/kg) (2, 3, 6,
8) and low dose IVIG (3-8 doses of 100 mg/kg) with PP (1,
2, 5, 7, 10, 12). We used low dose IVIG (6 doses of 200 mg/
kg) for consecutive sessions, because of the cost-effectiveness
of IVIG and the speculation that multiple doses of IVIG result
in prolonged modulation of DSA. The elimination rate of
DSA in our group was 100%, which shows that PP and low
dose IVIG is effective in eliminating DSA. Maintenance im-
munosuppressuion using FK506 and MMF was started 1 week
prior to transplantation to avoid overimmunosuppression
(21). The high DSA-elimination rate may explain the high
success rate and low AR rate in our patients.
We included rituximab after experiencing graft loss in a
previously crossmatch-positive patient (case 8). The patient
showed good graft function in the early posttransplant peri-
od, but lost graft function due to accelerated acute rejection
on day 7. At that time, the crossmatch test was positive and
DSA was documented by PRA. This finding provided the
importance of de no production of DSA after transplantation,
and led to the utilization of rituximab, a chimeric anti-CD20
monoclonal antibody, to prevent de novo production of alloan-
tibodies by memory B cells. In our study, we used two doses
of rituximab with one week interval (one week before and
one day before transplantation), and each dose was 375 mg/
m2. Until now, there is controversy regarding the time course
and dose of rituximab for preventing AMR. The validity of
using rituximab 1 week before transplantation is that action
of rituximab on the peripheral CD20
+ cells is rapid (Fig. 3)
and the half-life of rituximab is 9-14 days in patients with
end-stage renal disease (22). Single dose of rituximab may be
sufficient to prevent the production of alloantibodies (23).
However, recent reports show that single dose of rituximab
is not enough to prevent AMR (24), and this unsatisfactory
result may be related to the incomplete elimination of resid-
ual B cells in solid lymph organs (22, 24, 25). Therefore, it
seems reasonable to use two doses of rituximab before trans-
plantation.
There were two AR episodes in the early posttransplanta-
tion period. One presented as a slow decline in urine output
on posttransplant day 4 with no circulating DSA, and was
crossmatch-negative either by AHG-CDC or FCM. The graft
function improved with subsequent PP/IVIG and methyl-
prednisolone therapy (patient 5). An indication biopsy was
not performed because of thrombocytopenia. The other pre-
sented as accelerated acute rejection on posttransplant day 6
with circulating DSA (anti-A2 and anti-B45). We treated
this patient with PP/IVIG and methylprednisolone treatment
but it failed to reverse AMR (patient 8). Graft nephrectomy
was performed as signs of disseminated intravascular coagu-
lation occurred before trial of anti-thymoglobulin or OKT3.
This finding suggests that early posttransplant period (one
week after transplantation) is important to determine suc-S154 H.E. Yoon, B.J. Hyoung, H.S. Hwang, et al.
cessful transplantation in sensitized patients. 
In addition to low AR rate, long-term graft and patient
survival rates were excellent in our patients. Nine patients
(90%) are currently dialysis-free after a median follow-up of
22.6 months (range: 6.9-52.0), and there have been no more
AR episodes. The most recent serum creatinine concentration
is 1.0±0.2 mg/dL (range: 0.7-1.4, Fig. 4), and the patient
survival rate is 100%. This finding suggests that graft func-
tion can be maintained for a long time if sensitization treat-
ment is successful, as shown in ABO-incompatible transplan-
tation.
Detection of DSA is an important factor for determining
desensitization treatment. We recommended using rituximab,
but it may cause false positivity in cell-based crossmatch tests
because of its action mechanisms such as complement acti-
vation and binding of Fc portion (16). Therefore, solid-phase
crossmatch tests are needed in these patients. Indeed, two
patients with rituximab treatment were crossmatch-positive
both by AHG-CDC and FCM but negative by AMS, a solid
phase ELISA-based crossmatch test. Therefore, we recommend
setting up a solid-phase crossmatch before using rituximab
(10, 16). 
The use of protocol surveillance biopsies in our study allows
a more precise assessment of allograft function and early detec-
tion of the histological changes indicating AMR. Gloor and
colleagues (10) suggested that surveillance biopsies might be
an important adjunct for monitoring allograft function in sen-
sitized patients. Our transplant center has performed routine
protocol biopsies for 14 years in patients with stable graft
function on day 14 after transplantation. We previously report-
ed that a protocol biopsy performed in the early posttrans-
plantation period was useful for detecting subclinical rejec-
tion and predicting graft survival (26). To detect the pres-
ence of subclinical AMR, we performed C4d IF staining in
protocol biopsies. Table 4 shows that all patients who had a
protocol biopsy had minimal tissue injury and no deposits
of C4d. Although the prognosis of C4d positivity in proto-
col biopsies with stable graft function is still undetermined,
our results suggest that the desensitization was successful in
preventing subclinical AMR in these patients.
There was no procedure-related side effect of PP or infu-
sion-related side effect of rituximab. One patient developed
BK-viremia and viruria 6 months after transplantation. There
was no graft dysfunction, and it disappeared after reducing
the dose of FK506. No patient developed CMV infection.
Thrombocytopenia developed in two patients. But one patient
already had thrombocytopenia before desensitization thera-
py, and the other developed thrombocytopenia during AR.
Hematoma was observed in two patients, but it was related
to the surgical procedure (simultaneous bilateral nephrecto-
my and friable vessels) rather than the complication of desen-
sitization treatment. Therefore our desensitization protocol
was tolerable and safe.
In summary, the desensitization protocol should both elim-
inate DSA and prevent de novo production of alloantibodies.
It is clear that a desensitization strategy using PP/IVIG with
or without rituximab increases the likelihood of successful
living donor renal transplantation in highly sensitized recipi-
ents.
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